Hauser RA. Help cure Parkinson's disease: please don't waste the Golden Year. NPJ Parkinsons Dis 2018;4:29.
“Hauser RA. Help Cure Parkinson’s Disease: Please Don’t Waste the Golden Year. NPJ Parkinsons Dis 2018;4:29.”. 2018. NPJ Parkinsons Dis.
Search
Search results
193 results found
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 2017;74:216-224.
Schapira, AH, SH Fox, RA Hauser, J Jankovic, WH Jost, C Kennedy, J Kulisevsky, R Pahwa, W Poewe, and R Anand. 2017. “Assessment of Safety and Efficacy of Safinamide As a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 2017;74:216-224.”. JAMA Neurol.
Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. Am J Cardiol 2017;119:1111-1115.
White, WB, RA Hauser, GJ Rowse, A Ziemann, and LA Hewitt. 2017. “Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. Am J Cardiol 2017;119:1111-1115.”. Am J Cardiol.
A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.
Biglan, KM, D Oakes, AE Lang, RA Hauser, K Hodgeman, B Greco, J Lowell, et al. 2017. “A Novel Design of a Phase III Trial of Isradipine in Early Parkinson Disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.”. Ann Clin Transl Neurol.
Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B). Mov Disord 2015;30:646-54.
Hauser, RA, S Isaacson, JP Lisk, LA Arthur Hewitt, and G Rowse. 2015. “Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson’s Disease (nOH306B). Mov Disord 2015;30:646-54.”. Mov Disord.
Who is helping whom? Manuscript support and transfer of value. Ann Neurol 2015;77:353-5.
Wechsler, R, RA Hauser, and J French. 2015. “Who Is Helping Whom? Manuscript Support and Transfer of Value. Ann Neurol 2015;77:353-5.”. Ann Neurol.
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 2015:38:163-9.
Simon, DK, C Wu, BC Tilley, AM Wills, MJ Aminoff, J Bainbridge, RA Hauser, et al. 2015. “Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 2015:38:163-9.”. Clin Neuropharmacol.
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci 2018;128:619-626.
Lew, MF, A Breashear, K Dashtipour, S Isaacson, RA Hauser, P Maisonobe, D Snyder, and W Ondo. 2018. “A 500 U/2 mL Dilution of AbobotulinumtoxinA Vs. Placebo: Randomized Study in Cervical Dystonia. Int J Neurosci 2018;128:619-626.”. Int J Neurosci.
Hauser RA, Truong D. Tardive dyskinesia: Out of the shadows. J Neurol Sci 2018;389:1-3.
“Hauser RA, Truong D. Tardive Dyskinesia: Out of the Shadows. J Neurol Sci 2018;389:1-3.”. 2018. J Neurol Sci.
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord 2016;31:1366-72.
Hauser, RA, CW Olanow, B Dzyngel, T Bilbault, H Shill, S Isaacson, J Dubow, and A Agro. 2016. “Sublingual Apomorphine (APL-130277) for the Acute Conversion of OFF to ON in Parkinson’s Disease. Mov Disord 2016;31:1366-72.”. Mov Disord.